Instil Bio, INC Form 4 insider transactions
Insider transactions: buys and sells by directors, officers and ten percent owners, filed within two business days of the trade.
NASDAQ
Director R. Kent McGaughy Jr. was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.
NASDAQ
Director George Matcham was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.
NASDAQ
Director Neil W. Gibson was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.
NASDAQ
Director Gwendolyn Binder was granted 6,500 stock options in Instil Bio, Inc. as part of the company's equity incentive plan.
NASDAQ
Instil Bio's CFO and CBO, Sandeep Laumas, executed a pre-planned transaction, exercising stock options and simultaneously selling an equivalent number of common shares.
NASDAQ
Instil Bio, Inc. Director Gwendolyn Binder was granted 6,500 stock options with an exercise price of $26.75, vesting over 12 months.
NASDAQ
Instil Bio, Inc. Director Neil W. Gibson was granted 6,500 stock options with an exercise price of $26.75, vesting over 12 months, as disclosed in a recent SEC Form 4 filing.
NASDAQ
Instil Bio, Inc. Director George Matcham was granted 6,500 stock options with an exercise price of $26.75, vesting over 12 months or upon specific events.
NASDAQ
Instil Bio, Inc. Director and 10% Owner R Kent Jr McGaughy reported the acquisition of 6,500 stock options with an exercise price of $26.75, vesting over 12 months or upon specific conditions.
NASDAQ
Sandeep Laumas, CFO and CBO of Instil Bio, Inc., acquired 44,851 shares of common stock through an employee stock option on April 25, 2025.
NASDAQ
CEO Bronson Crouch of Instil Bio, Inc. reports the acquisition of stock options.
NASDAQ
Sandeep Laumas, CFO and CBO of Instil Bio, Inc., acquired 45,000 employee stock options on September 18, 2024.
NASDAQ
CEO and Chairman of Instil Bio, Bronson Crouch, reports the acquisition of 50,000 employee stock options.
NASDAQ
Director George Matcham of Instil Bio, Inc. reports the acquisition of 5,000 stock options with an exercise price of $10.50 on June 13, 2024.
NASDAQ
Director Gwendolyn Binder reports the acquisition of stock options in Instil Bio, Inc.
NASDAQ
R Kent Jr McGaughy, a director of Instil Bio, Inc., reported the acquisition of 5,000 stock options on June 13, 2024.
NASDAQ
Director Neil W. Gibson acquired 5,000 stock options in Instil Bio, Inc. on June 13, 2024, according to a Form 4 filing with the SEC.